(AVNR) Announces Positive Phase II Trial Results for AVP-923 In Alzheimer’s

– Significantly Improved Agitation in 220-Patient 10-week Study – – Company Plans to Meet with FDA to Discuss Initiation of Pivotal Development Program – – Data to be Presented at the American Neurological Association Meeting in October –

ALISO VIEJO, Calif., Sept. 15, 2014 — Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer’s disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression domain score of the neuropsychiatric inventory (NPI) compared to placebo (p=0.00008).  The reduction in agitation was observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design.

In addition, improvements were also seen in a majority of the secondary endpoints including the NPI total score (p=0.014), clinical global impression of change-agitation (p=0.0003), patient global impression of change (p=0.001) and measures of caregiver burden (p≤0.05).

“This is an exciting advancement in Alzheimer’s disease research,” said Jeffrey Cummings, MD, director of the Cleveland Clinic Lou Ruvo Center for Brain Health and chair of the study steering committee. “Dementia-related neuropsychiatric symptoms such as agitation are extremely distressing to patients and their families.”

“A potential new treatment option that could alleviate agitation or aggression as a result of Alzheimer’s disease would have a significant impact on the daily life of these patients and of their caregivers,” added Constantine Lyketsos, MD, director of the Johns Hopkins Memory and Alzheimer’s Treatment Center and also a member of the study steering committee.

“With no FDA approved drugs for the treatment of agitation in Alzheimer’s disease, we believe these results represent a breakthrough for patients,” said Joao Siffert, MD, chief medical officer at Avanir. “We are extremely excited with the prospect of bringing a potential treatment that can provide clinically meaningful relief to these patients and reduce caregiver burden. These study results represent the second neuropsychiatric disorder where AVP-923 has shown benefit and lends support for further advancement of our research programs into related disorders.”

Data from this phase II study will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October, 12-14, 2014.

Based on these results Avanir plans to request a meeting with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) with the intention of discussing advancement of its dextromethorphan programs into pivotal studies for the treatment of agitation in patients with Alzheimer’s disease.

AVP-923 was found to be generally well-tolerated in this phase II study. The most common adverse reactions were falls, diarrhea, and urinary tract infection occurring in less than 10 percent of patients. There was a low patient discontinuation rate and there were no serious adverse events that were deemed treatment related by the investigators. AVP-923 is known to have certain risks (see ‘About AVP-923’ section below).

About the Study Design
The objectives of this phase II study were to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of agitation in Alzheimer’s patients. The trial was a 10-week, multicenter, randomized, double-blind, placebo-controlled study utilizing a SPCD design intended to reduce placebo response rates. Enrollment was completed with 220 Alzheimer’s patients in the United States. Eligible patients were initially randomized 3:4 to receive either AVP-923 (dose escalated from DM 20mg/ Q 10mg to DM 30mg/ Q 10mg) or placebo. At the end of week 5, patients who initially received placebo were stratified according to their response to treatment and subsequently re-randomized 1:1 to receive either AVP-923 or placebo for the remainder of the study (an additional 5 weeks of treatment). Patients who initially received AVP-923 continued to receive AVP-923 DM 30mg/ Q 10mg for the remainder of the study. The main efficacy measure is the agitation/aggression subscale of the Neuropsychiatric Inventory or NPI. The primary endpoint follows a standard analysis of SPCD by combining the change from baseline to week 5 (stage 1: full analysis population) and change from week 5 to week 10 (stage 2) on the NPI agitation/aggression domain (patients who were considered “non-responders” to placebo during the initial 5 weeks). Secondary outcome measures include global assessments of disease severity, other neuropsychiatric symptoms, cognition, activities of daily living, quality of life and caregiver strain. Standard safety assessments will also be conducted.

About Agitation in Alzheimer’s Disease
An estimated six million Americans have Alzheimer’s disease, a number that has doubled since 1980 and is expected to be as high as 16 million by 2050. Alzheimer’s disease is generally characterized by cognitive decline, impaired performance of daily activities, and behavioral disturbances. Behavioral and psychiatric symptoms develop in as many as 60% of community-dwelling dementia patients and in more than 80% of patients with dementia living in nursing homes; as the disease progresses the  risk of such complications approaches 100%. Dementia-related behavioral symptoms, including agitation, can be extremely distressing to the individual, the family, and caregivers. These behavioral disturbances have been associated with more rapid cognitive decline, institutionalization, and increased caregiver burden.

About AVP-923
AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist, sigma-1 receptor agonist and inhibitor of the serotonin transporter (SERT) and norepinephrine (NET) transporter) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. AVP-923 is an investigational drug not approved by the FDA. AVP-923 is known to have certain cardiovascular risks and drug-drug interactions. Patients with history of certain cardiovascular risks and on certain drugs were excluded from the study.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir’s plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with delays in the release of study results, whether preclinical and clinical results for AVP-923 or other dextromethorphan drug products will be predictive of future clinical study results, whether regulatory agencies domestically and internationally will discuss advancement of one or more programs into pivotal studies, whether study data will be accepted for presentation and/or publication and whether a drug candidate can ultimately be successfully developed for commercialization, whether future clinical trials will be completed on time or at all, potential changes in cost, formulation, scope and duration of the clinical studies, obtaining additional indications for commercially marketed products domestically and internationally, obtaining and maintaining regulatory approvals domestically and internationally, whether new drugs can be successfully commercialized, and other risks detailed from time to time in the Company’s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

BrewLife Media Contact
Kelly France, PhD
kfrance@brewlife.com
+1 (415) 946-1076

(NETE) Net Element to Bring Apple Pay to Merchants

Offering mobile payments so more customers can pay when, where and how they want

MIAMI, Sept. 17, 2014  — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, today announces it will integrate Apple® services into its point-of-sale payment acceptance hardware and software, enabling Company merchants the ability to accept Apple Pay from customers. This new service will create a unique experience for customers who want to pay at the point-of-sale using their Apple® iPhone 6, Apple® iPhone 6 Plus and Apple® Watch devices.

When Apple Pay is available, customers can add their existing cards to the Apple Pay application. Anywhere they see the universal contactless acceptance symbol, customers can use the app on their Apple device to pay in person without physically swiping their card. Additionally, customers may use Apple Pay to make online purchases in apps with participating retailers while using their iPhone 6 and iPhone 6 Plus. Purchases are also protected by Zero Liability, which reimburses customers for promptly reported unauthorized transactions.

“With Apple Pay, an expected 60 million iPhone 6 and iPhone 6 Plus users will be ready to tap and pay anywhere contactless payments are accepted,” stated Oleg Firer, CEO of Net Element. “As part of our strategy to best capitalize on this massive opportunity and continue leading the mobile payment industry, we will be offering a free NFC Contactless, EMV-enabled point-of-sale terminal to merchants that upgrade to our Unified Payments service offering.”

About Net Element (NASDAQ: NETE)   

Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a next generation cloud-based point of sale payments platform; and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. More information is available at www.netelement.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict, Examples of such risks and uncertainties include, but are not limited to: (i) Net Element ‘s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element ‘s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element ‘s ability to successfully expand in existing markets and enter new markets; (iv) Net Element ‘s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element ‘s business; (viii) changes in government licensing and regulation that may adversely affect Net Element ‘s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element ‘s business; (x) Net Element ‘s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk that the U.S. government may decide to impose sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

(LAKE) Announces Global Availability of Hazmat Suits for Ebola

RONKONKOMA, N.Y., Sept. 12, 2014  — Lakeland Industries, Inc. (NASDAQ: LAKE), a leading global manufacturer of industrial protective clothing for industry, municipalities, healthcare and to first responders on the federal, state and local levels, today announced the global availability of its protective apparel for use in handling the Ebola virus.  In response to the increasing demand for specialty protective suits to be worm by healthcare workers and others being exposed to Ebola, Lakeland is increasing its manufacturing capacity for these garments and includes proprietary processes for specialized seam sealing, a far superior technology for protecting against viral hazards than non-sealed products.

Logo – http://photos.prnewswire.com/prnh/20120611/NY21959LOGO <http://photos.prnewswire.com/prnh/20120611/NY21959LOGO>

“Lakeland stands ready to join the fight against the spread of Ebola,” said Christopher J. Ryan, President and Chief Executive Officer of Lakeland Industries.  “We understand the difficulty of getting appropriate products through a procurement system that in times of crisis favors availability over specification, and we hope our added capacity will help alleviate that problem.  With the U.S. State Department alone putting out a bid for 160,000 suits, we encourage all protective apparel companies to increase their manufacturing capacity for sealed seam garments so that our industry can do its part in addressing this threat to global health.

Mr. Ryan continued, “With our diverse global operations and the breadth of our protective apparel line incorporating superior sealed seam technology, we are ideally situated to assist organizations worldwide as they handle Ebola.  Despite reports citing the short supply of protective suits for handling hazardous materials, we believe it is very important to alert those in need around the world that Lakeland has appropriately qualified and  certified suits, ample manufacturing capacity, and numerous distribution points to supply these garments.”

Last Friday, U.N. Secretary-General Ban Ki-moon laid out plans to set up an Ebola crisis center, with a mission to halt the spread of the virus in West African countries in six to nine months. He is counting on public and private funding from around the world of some$600 million needed for supplies in West Africa. Nearly 2,300 people have died and 4,300 confirmed or probable cases of Ebola have been reported since March.  Mr. Ban said in a statement, “The number of cases is rising exponentially. The disease is spreading far faster than the response. People are increasingly frustrated that it is not being controlled.”

Within the past several weeks, Lakeland has provided suits that are being used by Doctors Without Borders in West Africa.  Lakeland’s global team worked with leaders from Doctors Without Borders to ensure that the technical data and performance specifications for Lakeland’s garments exceeded the necessary protective requirements.

Two days ago, an NBC affiliate reported <http://www.nbcwashington.com/news/local/Non-Profit-Ships-276-Hazmat-Suits-Medical-Personnel-Ebola-Liberia-274683231.html> that PCI Global, a non-profit group with offices inWashington, DC, sent a quantity of hazmat suits toLiberia for use in the treatment of patients with Ebola.  “These suits are essential to saving lives,” said PCI Vice PresidentRichard Parker in the report.  “There’s a very short supply around the world.  We were able to procure these 276 suits through a medical supply company inCalifornia, so we bought them up as soon as we could.”  The suits that were procured and shipped were sealed seam garments manufactured by Lakeland Industries.

Lakeland’s ChemMAX 1 garments are being used in the fight against the Ebola virus based on their certification to EN 14126, the European standard for protective clothing for use against infective agents, and ASTM F1671 certification for protection from blood-borne pathogens along with its availability in sealed seam configurations.  Lakeland has the same certifications for other protective garments, including MicroMAX NS and the remaining ChemMAX product line.

For additional product information or to place an order, please visit www.lakeland.com <http://www.lakeland.com/> or contact customer service:

United States at +1-256-350-3873Argentina at +54-11-4897-5760Brazil at +55-11-3613-3700Canada at 800-489-9131Chile at +562-551-8562China at +010-6437-9226India at +91-8447556757Mexico at 800-837-9236Russia at +7-495-775-72-64UK at +44-14304-78140

About Lakeland Industries, Inc.:

Lakeland Industries, Inc. (NASDAQ: LAKE) manufactures and sells a comprehensive line of safety garments and accessories for the industrial protective clothing market.  The Company’s products are sold by a direct sales force and through independent sales representatives to a network of over 1,200 safety and mill supply distributors. These distributors in turn supply end user industrial customers such as chemical/petrochemical, automobile, steel, glass, construction, smelting, janitorial, pharmaceutical and high technology electronics manufacturers, as well as hospitals and laboratories. In addition, Lakeland supplies federal, state, and local government agencies, fire and police departments, airport crash rescue units, the Department of Defense, the Centers for Disease Control and Prevention, and many other federal and state agencies.  For more information concerning Lakeland, please visit the Company online atwww.lakeland.com <http://www.lakeland.com/>.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:  Forward-looking statements involve risks, uncertainties and assumptions as described from time to time in Press Releases and Forms 8-K, registration statements, quarterly and annual reports and other reports and filings filed with the Securities and Exchange Commission or made by management.  All statements, other than statements of historical facts, which address Lakeland’s expectations of sources or uses for capital or which express the Company’s expectation for the future with respect to financial performance or operating strategies can be identified as forward-looking statements.  As a result, there can be no assurance that Lakeland’s future results will not be materially different from those described herein as “believed,” “projected,” “planned,” “intended,” “anticipated,” “estimated” or “expected,” or other words which reflect the current view of the Company with respect to future events.  We caution readers that these forward-looking statements speak only as of the date hereof.  The Company hereby expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company’s expectations or any change in events conditions or circumstances on which such statement is based.

(MYHI) Completes Positive Greenhorn Property Due Diligence

(PMCM) Board of Directors Declares Stock Dividend, Spin-Out of ESMG

SEATTLE, Sept. 12, 2014  — Primco Management Inc. (OTCBB: PMCM), a medical marijuana, real estate management and multi-media company, today announced that the Company’s Board of Directors has declared a stock dividend of its ESMG, Inc. music division, effectively divesting the entertainment asset to become a newly traded stock on the OTCQB market.  Brandon Padilla, former Vice President of marketing at Virgin Records, has been appointed President.  Shareholders as of record date October 1, 2014, will receive one share of ESMG common for each 50 shares of Primco Management, Inc.

“By splitting Primco into two distinct trading companies, we can utilize the public markets to separately and effectively fund each operation independently with no ill effect on the other and zero dilution to any current Primco shareholder,” stated David Michery, CEO of Primco.  “I have great confidence in Brandon and am convinced that ESMG, as a separately traded entity, will greatly benefit all of our Primco shareholders in the long run.”

Brandon Padilla was a former Vice President of Marketing for Virgin Records and was credited as part of the team responsible for breaking the records of smash hit artists Daft Punk, Lenny Kravitz, Smashing Pumpkins and Mariah Carey.  Terms of Mr. Padilla’s employment agreement were not disclosed at this time.

In other news, Primco announced that it has completed the acquisition and consolidation of “My Suzy Q’s” and “Seattle Green Care” in Seattle, WA.

About Primco Management Inc.:

Through its wholly-owned subsidiaries, ESMG Inc., Top Sail Productions and D & B Music, Inc., the Company operates as an integrated entertainment company with divisions in music and film production and distribution. Primco also operates in various aspects of the real estate industry. (For additional information, visit www.primcousa.com).

Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.

Primco Management, Inc. (OTCBB:PMCM)
2211 Elliott Ave.
Suite 200
Seattle, WA 98121
United States
Phone: 206-455-2940
Email: contact@primcousa.com

(CGA) Reports Fiscal Year 2014 Financial Results

Provides Guidance on the First Fiscal Quarter 2015 and Fiscal Year 2015 Revenues and Net Incomes

XI’AN, China, Sept. 12, 2014  — China Green Agriculture, Inc. (NYSE: CGA; “China Green Agriculture” or the “Company”), a company that mainly produces and distributes humic acid-based compound fertilizers, varieties of compound fertilizers and agricultural products through its subsidiaries in China, today announced its financial results for the Fiscal Year ended June 30, 2014 and Guidance on Revenues and Net Incomes of the First Fiscal Quarter 2015 and Fiscal Year 2015.

Highlights:

• Sales increased 7.6% to $233.4 million; Net Income decreased 44.6% to $25.5 million; Earning per Share (EPS) of $0.81 in Fiscal Year 2014.
• First Fiscal Quarter 2015 Guidance: Revenue of $50.7 million to $54.3 million; Net Income of $5.9 million to $7.8 million; EPS of $0.18 to $0.24 based on 32.4 million fully diluted shares.
• Fiscal Year 2015 Guidance: Revenue of $254.7 million to $268.8 million; Net Income of $26 million to $35.1 million; EPS of $0.8 to $1.08 based on 32.4 million fully diluted shares.

Financial Summary

“As we concluded our recent fiscal year, we look forward to a year with no distractions and expenses from the recently resolved class action lawsuit. The new fiscal year will start with a particular focus on building Jinong’s and Gufeng’s fertilizer franchises as well as consolidating Yuxing’s operations to pursue growth in agriculture product revenue. Furthermore, as we enter into the new fiscal year, China Green Agriculture is on its way to achieving the early benchmarks of our ten-year plan that was announced in the year of 2011.”

Mr. Tao Li, Chairman and Chief Executive Officer of the Company, stated, “We are very pleased with our performance in business operation, generating $25.5 million net income in the year ended June 30, 2014,” he concluded, “Looking ahead to the Fiscal Year 2015, we expect revenue of $254.7 to $268.8 million; net income of $26 to $35.1 million; and EPS of $0.8 to $1.08 based on 32.4 million fully diluted shares. We are confident in accomplishing our goals in the next year.”

Fourth Fiscal Quarter 2014 Results of Operations

For the three months ended June 30, 2014, net sales were $72.2 million, an increase of $2.4 million, or 3.4%, from $69.8 million for the three months ended June 30, 2013. Among which, Gufeng contributed $41.7 million or 57.8% of total net sales, as compared to $36.3 million, or 52.0% of total net sales in the same period last year; Jinong’s net sales decreased $3.3 million, or 10.0%, to $29.5 million from $32.8 million in the same period last year; Yuxing’s net sales increased $0.3 million or 37.1%, to $1.0 million, as compared to $0.7 million for the same period last year. This Net Sales increase was mainly attributable to the greater sales of humic acid fertilizer products, including our liquid and powder fertilizers, as a result of our increased distributors and the aggressive marketing strategy.

Cost of goods sold increased $3.2 million, or 7.0%, to $48.5 million for the three months ended June 30, 2014, as compared to $45.3 million in the same period last year; gross profit decreased by $0.8 million, or 3.2%, to $23.7 million as compared to $24.5 million in the same period last year; gross profit margin was approximately 32.9% and 35.1% of net sale for the three months ended June 30, 2014 and 2013, respectively; selling expenses were $10.5 million, or 14.5%, as compared to $4.3 million, or 6.2% of net sales for the same period last year, an increase of $6.2 million, or 142.5%.

Besides, general and administrative expenses were $3.1 million or 4.4% of net sales, as compared to $2.3 million, or 3.3% of net sales in the same period of last year, an increase of $0.8 million or 39.8%; total operating expenses as a percentage of sales were 23.7%, as compared to 9.5% in the same period of last year; operating income was $6.6 million, a decrease of $11.3 million or 63.3%, from $17.9 million in the same period last year. Operating margin was 9.1%, compared to 25.8% in the same quarter of Fiscal Year 2013.

Finally, net income was $4.3 million, a decrease of $10.0 million or 75.3% as compared to $14.3 million in the same period last year. The decrease was attributable to the increase in selling expenses and impairment expenses.

Fiscal Year 2014 Results of Operations

For the year ended June 30, 2014, the company’s total net sales were $233,402,088, an increase of $16,504,132, or 7.6%, from $216,897,956 for the year ended June 30, 2013, due to an increase in Gufeng’s and Jinong’s net sales: Jinong’s net sales increased $7,121,011, or 6.4%, to $117,706,033 from $110,585,022 for the year ended June 30, 2013. This increase was mainly attributable to the greater sales of humic acid fertilizer products including our liquid and powder fertilizers during this period as a result of our increased distributors and the aggressive marketing strategy; net sales at Gufeng were $112,011,233, an increase of $9,095,819 or 8.8%, from $102,915,414 for the year ended June 30, 2013. The increase was mainly attributable to Gufeng’s expanded its marketing promotion strategy; Yuxing’s net sales were $3,684,822, an increase of $287,302 or 8.5%, from $3,397,520 in the same period of last year. The increase was mainly attributable to the development in sales of Yuxing’s top-grade flowers.

Total cost of goods sold for the year ended June 30, 2014 was $142,203,315, an increase of $4,689,213, or 3.4%, from $137,514,102 for the year ended June 30, 2013. Among which, cost of goods sold by Jinong was $48,629,095, a decrease of $3,254,840, or 6.3%, from $51,883,935 for the year ended June 30, 2013. The decrease was primarily attributable to lower product costs for the mix of products being sold; cost of goods sold by Gufeng was $90,748,540, an increase of $7,728,093, or 9.3%, from $83,020,447 for the year ended June 30, 2013. The increase was proportional to Gufeng’s sales increase for the year ended June 30, 2014; cost of goods sold by Yuxing was $2,825,680, an increase of $215,960, or 8.3%, from $2,609,720 in the same period of last year. The increase was proportional to Yuxing’s increased sales for the year ended June 30, 2014.

Total gross profit for the year ended June 30, 2014 increased by $11,814,919 to $91,198,773, as compared to $79,383,854 for the year ended June 30, 2013. Gross profit margin was 39.1% and 36.6% for the year ended June 30, 2014 and 2013, respectively. Among which, gross profit generated by Jinong increased by $10,375,851, or 17.7%, to $69,076,938 from $58,701,087 for the year ended June 30, 2013. Gross profit margin from Jinong’s sales was approximately 58.7% and 53.1% for the year ended June 30, 2014 and 2013, respectively. The increase was mainly due to the increased weight for higher-margin products sales in Jinong’s total sales; gross profit generated by Gufeng was $21,262,693, an increase of $1,367,726, or 6.9%, from $19,894,967 for the year ended June 30, 2013. Gross profit margin from Gufeng’s sales was approximately 19.0% and 19.3% for the year ended June 30, 2014 and 2013, respectively. The decrease was not significant; lastly, gross profit generated by Yuxing was $859,142, an increase of $71,342, or 9.1%, from $787,800 for the year ended June 30, 2013. The gross profit margin was approximately 23.3% and 23.2% for the year ended June 30, 2014 and 2013, respectively. The increase was not significant.

Our selling expenses consisted primarily of salaries of sales personnel, advertising and promotion expenses, freight-out costs and related compensation. Selling expenses were $36,203,414, or 15.5%, of net sales for the year ended June 30, 2014, as compared to $14,365,869 or 6.6% of net sales for the year ended June 30, 2013, an increase of $22,697,397, or 158.0%. The selling expenses of Gufeng were $1,304,511 or 1.16% of Gufeng’s net sales as compared to $1,136,672, or 1.10% of Gufeng’s net sales for the year ended June 30, 2013; The selling expenses of Jinong were $34,848,143 or 29.60% of Jinong’s net sales, as compared to selling expenses of $13,168,541, or 11.91% of Jinong’s net sales for the year ended June 30, 2013. Most of this increase in Jinong’s selling expenses was due to the amortization of $27,390,957 of the deferred assets, as compared to $9,970,715 for the year ended June 30, 2013, which was related to our business strategy implemented since the first quarter of Fiscal Year 2014 to assisting the distributors in certain marketing efforts and developing standard stores to expand our competitive advantage and market shares.

General and administrative expenses consisted primarily of related salaries, rental expenses, business development, depreciation and travel expenses incurred by our general and administrative departments and legal and professional expenses including expenses incurred and accrued for certain litigations. General and administrative expenses were $14,515,884, or 6.2% of net sales for the year ended June 30, 2014, as compared to $9,632,523, or 4.4%, of net sales for the year ended June 30, 2013, an increase of $4,883,361, or 50.7%. The increase was mainly due to the related expense in the stock compensation awarded to the employees which amounted to $8,119,724 as compared to $3,489,687 for the year ended June 30, 2013.

Finally, net income for the year ended June 30, 2014 was $25,514,695, a decrease of $19,259,353, or 43.0%, compared to $44,774,048 for the year ended June 30, 2013. The decrease was attributable to the increase in selling expenses and the impairment charge related to the write-down of assets held for sale. Net income as a percentage of total net sales was approximately 10.9% and 20.6% for the year ended June 30, 2014 and 2013, respectively.

Financial Condition

As of June 30, 2014, the Company held cash and cash equivalents of $26.9 million, a decrease of $48.1 million compared to $75.0 million as of June 30, 2013. The decrease in cash and cash equivalents was due to the incurrence of deferred assets of $61,799,672, as compared to $5,093,448 as of June 30, 2013. This was a result of the advance made by Jinong to the distributors in marketing the Company’s products with credit guarantee by Mr. Tao Li, Chairman and CEO of the Company. The Company had $24.0 million in short-term loans as of June 30, 2014, an increase of $7.9 million, as compared to $16.1 million  as of June 30, 2013. Net accounts receivable was $88.8 million, an increase of $3.5 million as compared to $85.3 million for the same period last year.

Others

On August 12, 2014, the United States District Court for the State of Nevada gave its final approval to the settlement of the securities class action pending against the Company and certain of its current and former officers and directors since October 15, 2010.  As a result, all securities law claims that had been filed against the Company have now been resolved and dismissed.

First Fiscal Quarter 2015 and Fiscal Year 2015 Guidance

For the first quarter ending September 30, 2014, management expects net sales of $50.7 to $54.3 million, net income of $5.9 to $7.8 million, and EPS of $0.18 to $0.24 based on 32.4 million fully diluted shares. For the Fiscal Year  2015, management expects net sales of $254.7 million to $268.8 million, net income of $26 million to $35.1 million, and an EPS of $0.8 to $1.08 based on 32.4 million fully diluted shares.

Conference Call

The Company will hold a conference call at 8:00 a.m. ET on Friday, September 12, 2014. Any interested participants are welcome to join in the call by following the dial-in details as set out below. When prompted by the operator, please indicate “China Green Agriculture’s Fiscal Year 2014 Financial Results” to join the call.

The call is being webcast by Vcall and can be accessed at China Green Agriculture’s website at http://www.ir-site.com/cgagri/events.asp. Investors can also access the webcast at http://www.InvestorCalendar.com.

A playback will be available through October 12, 2014. To listen, please call 1- 877-660-6853 within the United States or 1- 201-612-7415 when calling internationally. Replay Passcodes (both required for playback): Account #: 286; Conference ID #: 13590787.

About China Green Agriculture, Inc.

The Company produces and distributes humic acid-based compound fertilizers, blended fertilizers, organic compound fertilizers, mixed organic-inorganic compound fertilizers, slow-release fertilizers, highly concentrated water soluble fertilizers and agricultural products, such as top-grade fruits, vegetables, flowers and colored seedlings through its wholly-owned subsidiaries, Shaanxi TechTeam Jinong Humic Acid Product Co., Ltd. (“Jinong”), Beijing Gufeng Chemical Products Co., Ltd. (“Gufeng”) and a variable interest entity, Xi’an Hu County Yuxing Agriculture Technology Development Co., Ltd. (“Yuxing”). Jinong produced and sold 125 different kinds of fertilizer products as of June 30, 2014, all of which are certified by the government of the People’s Republic of China (“PRC”) as “Green Food Production Materials”, as certified by the China Green Food Development Center. Jinong currently markets its fertilizer products to private wholesalers and retailers of agricultural farm products through 926 distributors in 27 provinces, four autonomous regions, and 3 central government controlled municipalities in PRC. Gufeng, and its wholly-owned subsidiary, Beijing Tianjuyuan Fertilizer Co., Ltd., are Beijing-based producers of compound fertilizers, blended fertilizers, organic compound fertilizers, and mixed organic-inorganic compound fertilizers. As of June 30, 2014, Gufeng produced and sold 328 different kinds of fertilizer products, and marketed its products through 263 distributors among China. For more information, visit http://www.cgagri.com. The Company routinely posts important information on its website.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the Company’s business, products and financial results. The Company’s actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic, business and environment conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, the execution of its ten-year growth plan, a satisfactory conclusion of the pending securities class action litigation and various other factors beyond the Company’s control. All forward-looking statements are expressly qualified in their entirety by this Safe Harbor Statement and the risk factors detailed in the Company’s reports filed with the SEC. China Green Agriculture undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by applicable law or regulations.

For more information, please contact:

China Green Agriculture, Inc.
Mr. Fang Wang (English and Chinese)
Tel: +86-29-88266383
Email: wangfang@cgagri.com

(MRDDF) Director Resigns

Miranda Gold Corp. (“Miranda”) (TSX-V: MAD) reports that Steve Ristorcelli, has resigned as a director of Miranda. He has served as a non-executive independent director for the past 19 years.

“We appreciate the contribution Steve has made in serving as a director for Miranda, providing the board with additional technical support and oversight to Miranda” said Board Chairman and CEO, Ken Cunningham.

The Company has four remaining directors two of whom are independent. The Company intends to recruit a third independent director.

About Miranda

Miranda is a gold exploration company active in Nevada, Alaska and Colombia, whose emphasis is on generating gold exploration projects with world-class discovery potential. Miranda performs its own grass roots exploration and then employs a joint venture business model on its projects in order to maximize exposure to discovery while minimizing exploration risk. Miranda has ongoing relationships with Agnico Eagle Mines Ltd., Prism Resources, Montezuma Mines Inc., and Red Eagle Mining Corporation.

For more information related to Miranda: Joe Hebert, Executive Vice President 775-738-1877
www.mirandagold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

(MINE) VitaminFIZZ® Begins 2nd Production Run Ahead of Schedule

Minerco’s Level 5 to Have Black Raspberry, Strawberry Lemonade and Pineapple Coconut on Shelves in September

HOUSTON, Sept. 11, 2014  — Level 5 Beverage Company, Inc., a subsidiary of Minerco Resources, Inc. (OTCQB:MINE), begins the second production run of its functional sparkling waters, VitaminFIZZ® today. This production run includes three new VitaminFIZZ flavors: Black Raspberry, Strawberry Lemonade and Pineapple Coconut. Level 5 Beverage will be producing the three new flavors this run to deliver to retail outlets in New York and Southern California. Bottles will also be made available for purchase on Amazon.com.

“The response to VitaminFIZZ has been extremely positive,” said V. Scott Vanis, Minerco’s Chairman and CEO. “In fact, the response has been so robust that we have begun production on our three new flavors ahead of schedule. While we focus our efforts on NYC and Southern California, we see this as a good sign for upcoming rollouts into new markets.”

This second run comes after a successful initial launch of VitaminFIZZ in August that included distribution to New York and Southern California through distributors Drink King and Avanzar, respectively. The initial launch of VitaminFIZZ also included sales through Amazon.com. Approximately 10,000 cases of VitaminFIZZ have been sold (including Purchase Orders) in just the first 20 days. The first run of VitaminFIZZ in August produced over 15,000 cases in the three original flavors, Orange Mango, Strawberry Watermelon and Lemon Lime.

All VitaminFIZZ flavors offer 100% of the Recommended Daily Intake of Vitamin C, Vitamin B6 and Vitamin B12. VitaminFIZZ fans should expect to see the new flavors available in late September on shelves in the New York market, closely followed by California and online at Amazon.com.

“Our distribution paths are opening up faster than anticipated,” said Darin Ezra, CEO of Power Brands Consulting and Director of Level 5 Beverage. “Retailers and distributors alike are quickly finding value in the VitaminFIZZ brand and with this momentum, we expect to see strong penetration in the first two markets before the end of the year.”

About VitaminFIZZ®

VitaminFIZZ is a lightly sparkling, flavor-filled, refreshing beverage with an awesome boost of essential vitamins developed to quench your thirst, naturally. VitaminFIZZ is caffeine free, is Non GMO, has zero calories and contains 100% of recommended daily Vitamin B and Vitamin C. Awaken your taste buds. Now that’s refreshing. See more at: www.vitamin-fizz.com, www.twitter.com/vitaminfizz and www.facebook.com/drinkvitaminfizz.

About Minerco Resources, Inc.

Minerco Resources, Inc. (OTCQB:MINE), is the parent company of Level 5 Beverage Company, Inc. (Level 5), a specialty beverage company which develops, produces, markets and distributes a diversified portfolio of forward-thinking, good-for-you consumer brands. The Level 5 brand umbrella includes: VitaminFIZZ(R), Vitamin Creamer(R), Coffee Boost(TM), The Herbal Collection(TM) and LEVEL 5(R). http://minercoresources.com.

Public Disclosure

Details of the Company’s business, finances and agreements can be found as part of the Company’s continuous public disclosure as a fully reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, please visit: http://www.minercoresources.com. The above statements have not been evaluated by the Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure or prevent any disease.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations and assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Some of these uncertainties include, without limitation, the company’s ability to perform under existing contracts or to procure future contracts. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, successful implementation of our business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward-looking statements.

CONTACT: Jason Grimley
         Spelling Communications
         jasongrimley@spellcom.com
         323-309-8714

(BSRC) Teams With UCSB to Develop a Low Cost Supercapacitor for Solar Energy Storage

Nobel Laureate Leads the Research Team Developing the Company’s BioSuperCap(TM), a Patent-Pending Bio-Inspired Supercapacitor That Will Be Lower Cost and Higher Energy Than Conventional Supercapacitors

(APPG) Acquires Mobile App Concept to Empower Local Active Sports Enthusiasts

(EFOI) Receives the Single Largest Order in the Company’s History

SOLON, Ohio, Sept. 11, 2014  — Energy Focus, Inc. (Nasdaq:EFOI), a leader in LED lighting technologies, today announced that the Company has received a $7.7 million order for the United States Navy combatant ship forces. This order, most of which is expected to be delivered throughout the remainder of 2014, represents the single largest order in the Company’s history.

This new delivery order is entirely for Energy Focus’ Intellitube® LED retrofit tubes. This true plug and play technology allows for direct fit into existing fluorescent sockets with or without the ballast in place. The proprietary circuit and LED lamp designed by Energy Focus is now employed and installed in more than 140 naval vessels in the vast U.S. Navy military fleet, up from fewer than 20 in the beginning of 2014.

“Over the past year, we have built extensive relationships with the U.S. Navy at various levels from the Pentagon to the ship forces, which now are broadly aware of the economic and sustainability benefits of our LED technologies, as well as the availability of our LED products,” said Eric Hilliard, President and Chief Operating Officer of Energy Focus. “We are extremely excited about and grateful for the unwavering commitment to energy and maintenance savings, as well as carbon reductions made by the leadership in the U.S. Navy. We are equally committed to working with and supporting all constituencies from the Navy to expedite their LED adoption initiatives in the quarters and years to come.”

“We are absolutely honored with the confidence the U.S. Navy has placed in Energy Focus and our LED products,” said James Tu, Executive Chairman and Chief Executive Officer of Energy Focus. “With over three decades of advanced lighting development experience and a long-term research partnership with the U.S. government in LED lighting since 2002, Energy Focus remains the only Navy Military-Spec qualified LED replacement lamp provider. We are also proud to say there has been zero failure in the lamps we have put on U.S. Navy ships since our first installation in 2007. We plan and fully expect to leverage our proven technologies and the resounding successes we have had with the U.S. Navy to build our presence and leadership in the broader maritime market, including military and non-military vessels that together represent a total addressable market of over $4 billion.”

Forward Looking Statements

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Generally, these statements can be identified by the use of words such as “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “intends,” “plans,” “may,” “will,” “should,” “could,” “would” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from Energy Focus’ forward-looking statements. These risks and uncertainties include, but are not limited to: the timing of the shipment of orders in our backlog, the benefits and performance of our lighting products; our ability to expand our sales with existing customers and other customers in the maritime market; growth in the markets into which Energy Focus sells; conditions of the lighting industry and the economy in general; statements as to our competitive position; the development and marketing of new products; relationships with the U.S. Navy, customers and distributors; trends in the price and performance of light-emitting diode (“LED”) lighting products; and our strategy with regard to protecting our proprietary technology. For more information about potential factors that could affect the financial results of Energy Focus, please refer to the Company’s SEC reports, including its Annual Reports on Form 10-K and its quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof. Energy Focus disclaims any intention or obligation to update or revise any forward-looking statements.

CONTACT: Media and Investor Contact:
         Energy Focus, Inc.
         (440) 715-1300
         pr@energyfocusinc.com
         ir@energyfocusinc.com

(PLKD) “Where Healthy Begins” Campaign, to Begin Distribution to 7-Eleven Franchises

BURBANK, Calif., Sept. 11, 2014  — NYBD Holding, Inc. (OTCPK: PLKD), Pleasant Kids Inc, America’s premium supplier of naturally balanced alkaline water and all natural apple juice for children is pleased to announce that the Company will begin distribution of Pleasant Kids products to 7-Eleven franchises in South Florida. The initial roll out will commence with Pleasant Kids Products being available in over 30 select 7-Eleven locations with additional stores being added on a regular basis.

“We are very proud to have this opportunity to offer Pleasant Kids products to 7-Eleven franchises, the largest and most recognizable convenience store brand in the world,” commented Robert Rico, CEO of Pleasant Kids Inc. “We are off to a great start and based on our success with these select franchise locations, we expect to continue to expand our distribution footprint to potentially include all 7-Eleven franchises. We intend to undertake a very deliberate yet methodical approach towards increasing the Pleasant Kids footprint globally and this is the type of relationship that can expedite those efforts. The framework for our goal of experiencing exponential quarter over quarter growth is being laid out and we expect those results to begin to take us to the next level.”

Whats Next…

There will be no reverse split of our shares for the upcoming quarter. The board of directors has elected that there will be no reorganization of the companies common share for 2014.

Pleasant Kids can be found on the shelves of Price Choice Grocers, Presidente Supermarkets, Diamond Mart, C and B Distributers, R C Distributers, ICSSF Public Charter Schools, 7 Eleven Stores in South Florida, and  online at www.pleasantkids.com and many more coming soon.

As always we would like to thank all of our shareholders and will continue to operate our company in a manner that best serves you. We will continue to update as to our accomplishments on a regular basis.

About 7 Eleven

7‑Eleven is the world’s largest convenience store chain with more than 53,500 stores in 16 countries, of which close to 10,400 are in North America. The company operates franchises and licenses close to 8,700 convenience stores in the U.S. and Canada. Of the more than 7,800 stores the company operates and franchises in the United States, more than 6,200 are franchised. Outside of the U.S. and Canada, there are more than 44,800 7‑Eleven and other convenience stores in Japan, Taiwan, Thailand, South Korea, China, Malaysia, Mexico, Singapore, Australia, Philippines, Indonesia, Norway, Sweden and Denmark. In 2012, 7 Eleven Stores generated worldwide sales in excess of  84 Billion Dollars.

About Pleasant Kids Inc.

Headquartered in Burbank, CA. Pleasant Kids is America’s premium supplier of naturally balanced pH-8.0+spring(alkaline) “healthy water” for children. The company features copyrighted mascot characters. The brand focuses on a positive message of love, happiness, and joy for children of all ages. Additionally, all the products are eco-friendly, BPA free, Non-toxic, No Bisphenol A, and No Phthalates. Pleasant Kids, Inc. owns and operates Pleasant Kids EXTRA, Inc. EXTRA manages the intellectual copyrighted characters and makes them available for select and limited business development, sponsorship opportunities and licensing deals

Safe Harbor Statement

THIS NEWS RELEASE CONTAINS “FORWARD-LOOKING STATEMENTS”, AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS.STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS”ESTIMATE”, “ANTICIPATE”, “BELIEVE”, “PLAN” OR “EXPECT” OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS CONTAINED IN THIS NEWS RELEASE INCLUDE STATEMENTS RELATING TO AS WELL AS THE RISKS SHOWN IN THE COMPANY’S MOST RECENT ANNUAL AND QUARTERLY REPORTS ON FORM 10-K AND FORM 10-Q, RESPECTIVELY, AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL REQUIREMENTS AND THE COMPANY’S ABILITY AND LEVEL OF SUPPORT FOR ITS EXPLORATION AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY’S EXPLORATION EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY’S PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKES FULL RESPONSIBILITY FOR ITS CONTENTS. NO SECURITIES REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

For more information and all the latest from Pleasant Kids, Inc. (PLKD)
Please contact customer service at +1-855-710-KIDS or visit us at www.pleasantkids.com
Email us at info@pleasantkids.com
Pleasant Kids, Inc. 2600 West Olive, 5F Burbank, CA 91505

(VNRX) NuQ® Blood Test Detects 84% of Colorectal Cancers, Incl. Early & Late Stage

Topline Data from 1,000-Subject Independent Blinded Trial to be Presented 9am PT Today during Aegis Capital 2014 Healthcare & Technology Conference; webcast at volitionrx.com

NAMUR, Belgium, Sept. 11, 2014  — VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types, today announced that CEO Cameron Reynolds will this morning present topline data from its 4,800-subject colorectal cancer trial at Hvidovre Hospital, Copenhagen, Denmark. Mr. Reynolds will present data from an initial representative 938-subject sample, demonstrating that the Company is able to correctly diagnose 84% of colorectal cancers, including early-stage cancers, using its NuQ® blood-based diagnostic platform.

Mr. Reynolds will discuss the data during a presentation at the 2014 Aegis Capital Healthcare & Technology Conference today at 9:00 a.m. U.S. Pacific Time. Mr. Reynolds’ presentation will be available from today on the Company’s website at www.volitionrx.com.

Despite the existence of screening programs for the disease, colorectal cancer remains the second leading cause of cancer-related death in the U.S.[i], partly due to the cost, and to low compliance with colonoscopies and other screening methods like fecal tests. Furthermore, colorectal cancer is often found after symptoms appear, which typically only happens with more advanced disease[i]. However, colorectal cancer is one of the more survivable diseases if caught early: it has an observed five-year survival rate of 74% in stage I, but only 6% in stage IV[i]. Put simply, many lives could be saved if colorectal cancer were caught earlier. VolitionRx’s NuQ® test aims to meet this need by detecting colorectal cancer through a simple, accurate, cost-effective, blood test.

Analysis of the 938-subject sample of the study demonstrated that the NuQ® diagnostic test detected 84 percent of colorectal cancers at 78% specificity, and 60 percent of polyps, in a population aged over 50 years with symptoms indicative of colorectal cancer. The NuQ® test used to achieve these results was a panel of three individual NuQ® assays, each of which identifies and measures a separate nucleosome structure in the blood. Each NuQ® panel used a small amount of blood – only 60µL or about a drop per subject. Data showed that the NuQ® test is able to detect early stage (I or II) disease and late-stage (III or IV) disease with similar accuracy, allowing for earlier detection and treatment of colorectal cancer and enabling the potential for improved patient outcomes.

Dr. Jake Micallef, Chief Scientific Officer of VolitionRx, commented, “VolitionRx has shown similar results previously in smaller colorectal cancer studies but confirmation that NuQ® tests are effective in a large, blind study is a landmark result for us. Moreover, the Nucleosomics® technology is not limited to the three assays used in this study, but incorporates hundreds of potential epigenetic NuQ® tests that may have applicability in colorectal and other cancers. We will share further analysis of the results from these 938 subjects at the 9th International Conference of Anticancer Research in October this year.”

Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital in Denmark, remarked, “This is an extremely promising result in a symptomatic population. Collection has now begun for a much larger 14,000-subject screening study in Denmark, and we expect to begin delivering the first several thousand samples to VolitionRx for analysis in the early part of 2015.”

Cameron Reynolds, Chief Executive Officer of VolitionRx Limited, commented, “An accurate, early, and cost effective blood test to screen for colorectal cancer would mark a revolutionary advancement in the way we test for and diagnose this terrible disease. These exciting results from our latest analysis, which demonstrated 84% accuracy in colorectal cancer detection, confirm that the NuQ® test enables accurate early identification of colorectal cancer through a simple blood test.”

VolitionRx has today closed a fund raise of $1.127 million. The raise consists of 512,614 shares at $2.20 (including insider conversions of $46,748). Monies raised will go towards VolitionRx’s ongoing operations and clinical trials.

VolitionRx will host a conference call to discuss this data, raise and the Company’s ongoing strategy on Tuesday, September 16 at 10 a.m. US Eastern Time. To attend the call, please use the information below for dial-in access. When prompted on dial-in, please utilize the conference ID or ask for the “VolitionRx Limited Investor Conference Call.”

Please dial in at least 10 minutes before the call to ensure timely participation. A playback will be available through September 30, 2014. To listen, please call +1-877-870-5176 within the United States or +1-858-384-5517 if calling internationally. Utilize the pass code 64623766 for the replay.

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

Visit VolitionRx’s website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

About the Trial

This representative blinded 938-subject sample (these results were CRC versus no findings on colonoscopy and no comorbidities) was drawn from a 4,800 symptomatic-subject study conducted at Hvidovre Hospital, Copenhagen, Denmark. Samples were collected from 2010 to 2012 from subjects with colorectal cancer, polyps or adenomas, benign bowel diseases or other malignancies, all of whom have undergone a colonoscopy. Under the trial design, VolitionRx has full anonymized access to all Danish national registries and databases. The study group were all aged over 50; results were age- and gender-adjusted.

Safe Harbor Statement

Statements in this press release may be “forward-looking statements”. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

Media Contacts

Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: Charlotte.Reynolds@volitionrx.com

Kirsten Thomas, The Ruth Group
kthomas@theruthgroup.com
Telephone: +1 (646) 536-7014

Investor Contacts

Scott Powell, VolitionRx
S.Powell@volitionrx.com
Telephone: +1 (917) 721-9480

Lee Roth, The Ruth Group
lroth@theruthgroup.com
Telephone: +1 (646) 536-7012

(FBCD) Receives Additional Purchase Order For 100,000 Compression Knee Sleeves

NEW YORK, NY, United States, via ETELIGIS INC., 09/10/2014 – – FBC Holding, Inc. (PINKSHEETS: FBCD) (FBC or the Company) an international product development company primarily focused on license/creation management and product sales/distribution through DRTV, announced that the company received an additional purchase order for 100,000 units for a compression knee sleeve.

Understanding that our goal was to utilize our contacts within the industry and build a product that would be successful, not only by the company but ultimately the consumer. Having delivered approximately 1.4 million compression knee sleeves to date and now receiving this additional 100,000 unit order, is very exciting for our company said Mr. Frank Russo, Chief Executive Officer of FBC Holding, Inc. To date the total retail value of all the orders have reached approximately $15 million and has been an extremely successful venture for our company in such a short period of time.

Having executed this project really opened our eyes, seeing that the marketplace is accepting of compression fabrics that have been infused with copper. With that said, we are not only exploring sports related support items but looking at products that are used in our everyday life stated Mr. Russo, One of our goals is to introduce an item or items that have value, serve a benefit for the consumer and drive revenue for the company. Margin is the key to a successful business model and our focus is on the $15 million program that has been delivered to date. We learned many valuable lessons during this process, most importantly controlling our own destiny in order to capitalize on our own ability to develop, manufacturer and deliver product under the Copper-Tech brand.

Having the ability to develop the fabric from the yarn level has provided our company with the following benefits: 1) Retention of copper in the yarn of 99.9% after 30 wash cycles, 2) Anti-Microbial properties that kill fungus, bacteria and have odor eliminating properties as well, 3) Kills approximately 70% of P-Acne and 4) Reduction of body heat by 30 degrees Fahrenheit over a 40 minute frame. With these benefits, we are now awaiting finished samples that will reflect the above mentioned benefits that we can review and potentially make changes to construction, confirming fit and sizing.

About FBC Interactive Division

FBC Holdings Interactive Division markets innovative products generally incorporating new proprietary technologies. FBC Interactive, leverages Direct Response Television (DRTV) formats to advertise, market and distribute its products; gaining retail footholds in various markets. FBC Interactives market place is diverse, with a primary focus and expertise in toy and entertainment, consumer and health care, products and brands.

About FBC Holding, Inc.

FBC Holdings develops and markets innovative products using a new proprietary technology whereby buttons, switches, wires and other electrical components can be printed on nearly any media. Management is experienced in Direct to Consumer Marketing (design, manufacture and market creative products leveraging cutting edge technology). FBCs market is diverse, covering consumer products, health care related products, and, toy and entertainment products.

Safe Harbor

This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled “Risk Factors” in the Company’s periodic filings with the United States Securities and Exchange Commission, which can be viewed at http://www.SEC.gov. For all details regarding working interests in all of FBC Holdings interest, and/or any previous news releases, go to OTC Markets website. You should independently investigate and fully understand all risks before making investment decisions.

Related Links:

http://finance.yahoo.com/news/fbc-holding-positioned-rapid-growth-142935672.html

http://finance.yahoo.com/news/fbc-interactives-direct-response-marketing-140000170.html

For Investor Relations,

FBC Holding, Inc.

info@fbcholdinginc.com

(TBEV) Completes $1.5 Million Dollar Private Placement

CAVE CREEK, AZ, United States, via ETELIGIS INC., 09/10/2014 – – High Performance Beverage Co. (OTC Pink: TBEV) (PINKSHEETS: TBEV) (the “Company”) is pleased to announce it has closed its $1.5 million dollar Private Placement financing.

The $1.5 million will come in the form of three separate tranches of $500,000 over the next several months as the company implements its core business model which will also include the introduction of additional beverage flavors and potential trend beverage mixtures throughout the year.

The Company still anticipates putting its Throwdown High Performance drink into full production for a dual coast distribution during the month of October 2014.

Toby McBride, High Performance Beverage Company CEO, stated, “We are very pleased to announce the closing of our Private Placement. We are currently awaiting the first initial $500,000 as we draw closer to putting Throwdown High Performance Beverages into full production. Distributors on both east and west coasts are prepared to put TBEVs product line on retailer shelves.

The Company is also pleased to announce it has completed the revamping of its Company website. Upon initial distribution of TBEVs product lines all beverages will be available for retail purchase on the website.

About High Performance Beverage Company

High Performance Beverage Company has created a new beverage segment, under the trade name, Throwdown Performance Beverages, which manufactures and distributes a line of sport performance beverages. High Performance Beverage Company’s sport performance drinks are carefully formulated to support mental focus and help increase blood flow, thereby giving the body the necessary fuel to power through a specific event or throughout the day. Our unique blends are designed to bridge the gap between supplements, energy and hydration drinks, ultimately broadening our appeal and providing access to an expanding target market. High Performance beverages are sugar free and extremely low in both calories and caffeine. This positioning makes High Performance Beverage Co. beverages first to market with a sustainable competitive advantage.

Safe Harbor

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of High Performance Beverage Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond High Performance Beverage Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in High Performance Beverage Company’s filings with the Securities and Exchange Commission.

High Performance Beverage Co.

Public Relations and Shareholder Information

Joseph M. Vazquez III

Phone: (800) 767-9396

Email: infinityglobalconsulting@gmail.com

(TEVE) HyperCaster 4K Broadcaster Awarded Four Diamonds by BTR

(NXHD) Next Slide the City™ Event: Los Angeles, California — September 28, 2014

(FRZT) Partners W/ HighWater Group to Launch ‘Party Animals: Dance Battle’

TUSTIN, Calif., Sept. 10, 2014 — Freeze Tag (OTC:FRZT), a leading creator of mobile social games, today announced that it has selected HighWater Group as its marketing and PR agency to support the launch of its anxiously awaited free-to-play mobile game, Party Animals: Dance Battle.

“The app space is incredibly competitive and you need a savvy, integrated program to gain lift above the competitive din,” said Craig Holland, CEO, for Freeze Tag, Inc. “HighWater Group has the proven expertise within the mobile sector to help us gain traction with players.”

The collaborative partnership pairs the creative and interactive vision of Freeze Tag with the marketing and publicity acumen of HighWater Group. The integrated team is supported by an advanced set of metrics able to maximize monetization and player enjoyment while minimizing game disruption.

Set for a world-wide launch next month across iOS and Android app stores, Party Animals: Dance Battle is a fast-paced, multiplayer action game where battles are done on the dance floor.

About Freeze Tag, Inc.

Freeze Tag, Inc. is a leading creator of mobile social games that are fun and engaging for all ages. Based on a free-to-play business model that has propelled games like Candy Crush Saga to worldwide success, we employ state-of-the-art data analytics and proprietary technology to dynamically optimize the gaming experience for revenue generation. Players can download and enjoy our games for free, or they can purchase virtual items and additional features within the game to increase the fun factor. Our games encourage players to compete and engage with their friends on major social networks such as Facebook and Twitter. Founded by gaming industry veterans, Freeze Tag has launched several successful mobile games including the number one hit series Victorian Mysteries® and Unsolved Mystery Club®, as well as digital entertainment like Etch A Sketch®. Freeze Tag games have been downloaded millions of times on the Apple, Amazon and Google app stores.

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Freeze Tag, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Freeze Tag, Inc. undertakes no obligation to revise these statements following the date of this news release.

CONTACT: info@freezetag.com
         714-210-3850 x26

(FLRE) Begins Shipping Cannadol Hemp Oil Orders

Company Plans on Introducing Second CBD (“Cannabidiol”) Product Within Days Company to Open Amazon Webstore to Further Drive Online Revenues

VENICE, Fla., Sept. 10, 2014  — Flameret, Inc. (OTC: FLRE) announced today that Royal Hemp Corporation, its wholly-owned Colorado subsidiary, has begun shipping high CBD hemp oil orders. The company previously announced the launch of Cannadol™, its high CBD (cannabidiol) hemp oil. Over the first three days after the product launch was announced, the company received orders from 21 different customers. Further details regarding initial revenues will be announced in the company’s financial statements that will be filed at http://www.otcmarkets.com.

Cannadol™ is a dietary supplement sold as a hemp oil rich in CBD. It consists of 200mg of cannabidiol cold pressed from industrial hemp in an oral suspension of 1 ounce of hemp oil. None of the statements regarding Cannadol™ or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.

Scientific and clinical studies continue to underscore CBD’s potential as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic capabilities, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.

John Meredith, Chief Executive Officer of Flameret, Inc. remarked, “The launch of Cannadol™ and the response from consumers has far surpassed our internal expectations. We expect to deliver more good news to the investment public within a week.”

Mr. Meredith added, “It is very important as we update investors on our progress that investors also understand that we fully intend on pursuing what we perceive to be a large business opportunity in the flame retardant industry. There seems to be a misconception that we have abandoned that pursuit, however, nothing can be further from the truth. We have recognized an opportunity and we also had confidence that we can get a hemp-based product out on the market quickly. We have done that and our pursuit of a major business opportunity in the flame retardant industry continues.”

About Flameret

Flameret, Inc. has developed fire retardant products to suit a wide range of applications. These products are marketed under the brand names; Flameret, Flamex, Ultra Flamex and Impex. Flameret™ products are patented and held in the name of United American Inc.

The company is also in the process of launching a new line of products derived from industrial hemp which will be marketed and sold through Royal Hemp Corporation.

About Royal Hemp Corporation

Royal Hemp Corporation is a Colorado corporation which was created to market and sell hemp-based nutraceuticals, industrial products and consumer goods in the United States and throughout the world. All of the corporation’s products will be legal to sell in all states in the United States and in many countries throughout the world.

The press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company’s development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company’s products, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, and the Company’s ability to obtain additional financing. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

Contact: John Meredith: jwsmeredith@aol.com
+44 1732 460224

(AKER) $864,000 Sales Contract for Its Rapid Results Point of Care Cholesterol Test

New Cholesterol Test Takes Only Three Minutes to Produce Results; Addresses a Worldwide Market Estimated at $2 Billion

THOROFARE, N.J., Sept. 9, 2014  — Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), (the “Company” or “ABI”), a leading designer and manufacturer of rapid diagnostic screening and testing products, announced a contract valued at $864,000 for sales of its innovative Tri-Cholesterol “Check” tests in Australia, Singapore, the United Arab Emirates and Oman. The Company’s products are being distributed in such regions by 36 Strategies General Trading LLC (“36S”), a Dubai-based procurement solutions company. Target customers in Australia, Singapore, the United Arab Emirates and Oman include military forces, medical associations, universities and large companies operating in the resources sector.

The Company’s Tri-Cholesterol “Check” is a revolutionary finger-stick blood sample technology and the only combined rapid test which provides an estimate of both Total and High Density Lipoprotein (“HDL”) cholesterol levels;  thereby providing an estimate of the subject’s Low Density Lipoprotein (“LDL”) levels.

ABI’s Tri-Cholesterol “Check” test carries a U.S. Food and Drug Administration (“FDA”) Over-the-Counter approval; three CE marks for the European Economic Area; and a Health Canada approval.

Raymond F. Akers Jr., Ph.D, Executive Chairman of Akers Biosciences, stated, “This order gives us confidence that this test could become a very important and widely used test worldwide. There are an estimated 200 million people worldwide who have abnormal cholesterol levels. Our self-administered point-of-care test for cholesterol is easy-to-use, low cost, and revolutionary in point-of-care diagnostics. We are very pleased with the sales results we have achieved in these regions in a very short time through our distribution partner in the Middle East.”

Revenue related to this order for Tri-Cholesterol “Check” tests (a Rapid Enzymatic Assay product) was recognized in the accounts for the six months ended June 30, 2014.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found on our website at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend” and “expect” and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information:

         Raymond F. Akers, Jr. PhD
         Executive Chairman of the Board
         Akers Biosciences, Inc.
         Tel: +1 856 848 8698

         Brendan Hopkins
         RedChip Companies, Inc. (US Investor Relations)
         Tel: +1 407 644 4256 x134

         finnCap (UK Nominated Adviser and Broker)
         Geoff Nash / Scott Mathieson (Corporate Finance)
         Steve Norcross (Broking)
         Tel: +44 (0)20 7220 0500

         Ben Simons / Alexandra Roper
         Vigo Communications (UK Investor Relations)
         Tel: +44 (0)20 7016 9570
         akers@vigocomms.com

(MNTR) and Cannabis Edibles on Cover of Food & Drink

Marijuana Infused Products are Explained in First Full Length Cannabis Article by Thought Leading International Food Magazine

Mentor Capital, Inc. (OTC Markets: MNTR) announced it is pleased to be on the cover and featured in the “Budding Opportunities” Fall 2014 edition of Food & Drink which explores the “emerging world of cannabis edibles.” Over a range of topics and in plain terms, the article explains how and how much heating of marijuana by smoking or baking activates the psychoactive THC. This gave birth to the joint and the magic brownies of the 60’s. These mainstays are now being updated with vape systems and cannabis infused edible products. Similarly, the tried and true process of extracting the active marijuana oils by making cannabutter on the stove top is described. Here, the most modern approach is to now use liquefied CO₂ at 1,000 atmospheres which also dissolves oils. Reducing the pressure releases the gas leaving only the very pure cannabis extract behind.

For Mentor Capital to be featured in a main stream publication that has also featured the likes of Bacardi and McDonalds is a testament to the evolving acceptance of legalized medical marijuana and casual use across America, according to the company. With the Food & Drink writers, Mentor Capital was able to introduce the general public audience to the entrepreneurial story of Dixie Elixirs, G Farma Labs, Mountain High Products, Bhang Chocolate, Incredible Edibles, Kiva Confections, Gel-Stat and other cannabis industry leaders.

Food & Drink has a written circulation of 500,000 and the Fall 2014 “Budding Opportunities” edition is now widely available. Interested readers may also receive a free copy of the article at no charge by requesting a copy from Mentor Capital. The complete text is available at both the Mentor Capital and Food & Drink websites and at the link: http://mentorcapital.com/mentor-capital-featured-food-drink-magazine-click-view-article/

About Mentor Capital: By acquisition or stock purchase, Mentor Capital, Inc. seeks to invest in leading cannabis companies. Additional important information for investors and founders seeking expansion funding is presented at: www.MentorCapital.com

This press release is neither an offer to sell, nor a solicitation of offers to purchase, securities.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” or “intends,” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales activities, problems securing the necessary financing to continue operations, problems encountered in commercializing cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, difficulties in recruiting knowledgeable personnel and potential problems in protecting intellectual property. Further information concerning these and other risks is included in the Company’s 15c2-11 filing which, along with other very important information about the Company, can be found here: http://mentorcapital.com/disclosures/

The Company undertakes no obligation to update or revise such forward-looking statements to reflect events or circumstances occurring after the date of this press release.

(PROW) Announces Approval of U.S. Patent Claims

Mobile Broadcasting Corp.
Kenneth D. Bland
Chief Executive Officer
ken@briken.net

(ADCS) Shareholder Update

(SCOK) New Underground Coal Gasification Project $30-45 Million Expected in 2015

PINGDINGSHAN, China, Sept. 9, 2014  — SinoCoking Coal and Coke Chemical Industries, Inc. (Nasdaq:SCOK), a vertically-integrated coal and coke processor, today said it has signed an exclusive agreement with both the Institute of Process Engineering of the Chinese Academy of Sciences and the North China Institute of Science and Technology to refine and implement a technology that will be used, beginning next month, to convert the 21 million tons of coal at four SinoCoking underground mines into syngas, a clean burning fuel.

The technology will accomplish this conversion without releasing meaningful levels of carbon dioxide or other greenhouse gases above ground, said SinoCoking.

Located in Henan Province, these mines have been shut down for three years due to Chinese government-mandated mine consolidation guidelines. Now, however, these properties can be reactivated and their resources utilized in an environmentally friendly manner, said the company.

The first phase of the project, which will cost approximately $18 million and be funded primarily from SinoCoking’s cash reserves, is expected to be completed in February 2015 and yield a combined syngas output of 60,000 cubic meters per hour. This output will produce incremental gross profit in 2015 of from $30 to $45 million, said SinoCoking.

Subsequent phases of the project, expected to be completed by the end of 2016, will cost about $280 million and will be funded primarily from bank loans and company-issued debt. At completion, the project is expected to have an output capacity, subject to market demand, of 880,000 cubic meters of syngas per hour.

Customers for this syngas will be comprised primarily of local power, chemical and transportation companies as well as households requiring electricity in Henan Province, said SinoCoking.

“We are thrilled and honored to be working with the Institute of Process Engineering and North China Institute of Science and Technology on this vital project,” said SinoCoking Chairman and CEO Mr. Jianhua Lv. “The production of this vast new quantity of syngas – a clean burning fuel – while preventing the escape of carbon dioxide and other greenhouse gases, is, we believe, a major technological accomplishment.

“Combined with the opening, next month, of our above ground syngas facility in Pingdingshan, this new project further establishes our company as one of China’s leading producers of clean energy products.”

Mr. Lv said that SinoCoking would announce additional details on the construction and financing of the underground facility “in the near future.”

About SinoCoking

SinoCoking and Coke Chemical Industries, Inc. (www.scokchina.com), a Florida corporation, is a vertically-integrated coal and coke processor that uses coal from both its own mines and that of third-party mines to produce basic and value-added coal products for steel manufacturers, power generators, and various industrial users. SinoCoking has been producing metallurgical coke since 2002, and acts as a key supplier to regional steel producers in central China. SinoCoking also produces and supplies thermal coal to its customers in central China. SinoCoking currently owns its assets and conducts its operations through its subsidiaries, Top Favour Limited and PingdingshanHongyuan Energy Science and Technology Development Co., Ltd., and its affiliated companies, Henan Province PingdingshanHongli Coal & Coke Co., Ltd., Baofeng Coking Factory, BaofengHongchang Coal Co., Ltd., BaofengHongguang Environment Protection Electricity Generating Co., Ltd., Zhonghong Energy Investment Company, Henan Hongyuan Coal Seam Gas Engineering Technology Co., Ltd., BaofengShuangri Coal Mining Co., Ltd., and BaofengXingsheng Coal Mining Co., Ltd.

For further information about SinoCoking, please refer to our periodic reports filed with the Securities and Exchange Commission.

Forward Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans”, “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think”, “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place undue reliance on such statements. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may differ materially from the Company’s expectations and estimates. The Company provides no assurances that any potential acquisitions will actually be consummated, or if consummated that such acquisitions will be on terms and conditions anticipated on the date of this press release, and the Company makes no assurances with regard to any results of any such acquisitions.

(FRHV) Announces New Business Model Focused on Enterprise and Mobile Software Applications

NEW YORK, NY / September 9, 2014 / Fresh Harvest Products, Inc. “Fresh Harvest” (OTC: FRHV) today announced the Company’s new business model to become a leading technology solutions provider focused on the development of enterprise software, software as a service (SaaS) and mobile applications for the natural food, health and wellness markets.

Fresh Harvest previously operated as a natural and organic food products company before management decided to transition the Company’s line of business to capitalize on its relationships within the rapidly growing SaaS, enterprise software and mobile application markets.

The Company expects to develop, license and acquire software applications that will generate revenue through subscription fees, in-app upgrades, purchases and advertising. Fresh Harvest plans to launch a new corporate website with information pertinent to its new business operations in the near future.

“Fresh Harvest is pleased to announce our plans to enter the cloud-based SaaS, enterprise software
and mobile app markets. In line with its new direction, the Company plans to explore several business opportunities including strategic acquisitions and the development of software and mobile applications,” commented the Company’s President and CEO, Michael J. Friedman.

“The Company expects to bring on new executives with experience and relationships that will help us succeed as a technology solutions provider as well as become current with our financials in the near future. We look forward to updating our shareholders on the Company’s progress and milestones while we aggressively ramp up business operations in our new industry,” added Mr. Friedman.

Software as a service (SaaS) is a software delivery method that provides access to software and its functions remotely as a web-based service which allows organizations to access business functionality
at a lower cost than paying for licensed applications. SaaS also eliminates hardware costs because the software is hosted remotely.

About Fresh Harvest Products, Inc.

Fresh Harvest Products, Inc. based in New York City is a technology solution provider focused on the development of enterprise software, software as a service (SaaS) and mobile applications for the health and wellness markets.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
888-959-7095
ir@sealpointconsulting.com

(ALIF) Buys Back Shares

(BNNY) to be Acquired by General Mills for $46 Per Share in Cash

Companies Partnering to Accelerate the Growth and Development of the Annie’s Brand

BERKELEY, Calif., Sept. 8, 2014  — Annie’s Inc. (NYSE:BNNY) (“Annie’s”), a leading natural and organic food company, announced today a definitive agreement to be acquired by General Mills, Inc. (NYSE: GIS) (“General Mills”) for $46.00 per share in cash, for a total transaction value of approximately $820 million.  This acquisition will enable Annie’s to enter a new phase of growth and success while maximizing value for stockholders. The transaction consideration represents a 51% premium over Annie’s 30-day average closing price of $30.47 as of September 5, 2014. Annie’s will continue to be headquartered in Berkeley, California.

“We are excited about this strategic combination, which will enable Annie’s to expand the reach and breadth of our high quality, great tasting organic and natural products, provide new opportunities for our employees, realize greater efficiencies in our operations, and maximize value for our stockholders,” said John Foraker, Chief Executive Officer of Annie’s. “Powerful consumer shifts toward products with simple, organic and natural ingredients from companies that share consumers’ core values show no signs of letting up.  Partnering with a company of General Mills’ scale and resources will strengthen our position at the forefront of this trend, enabling us to more rapidly and efficiently expand into new channels and product lines in a rapidly evolving industry environment.

“Annie’s will remain dedicated to our mission: to cultivate a healthier and happier world by spreading goodness through nourishing foods, honest words and conduct that is considerate and forever kind to the planet.  Authentic roots, great tasting products, high quality organic and natural ingredients, and sustainable business practices will continue to be the cornerstones of the Annie’s brand,” concluded Foraker.

Molly Ashby, Annie’s Chairman of the Board of Directors, stated, “This transaction is a testament to the great team at Annie’s. Together, they have built a highly successful company around the authentic, mission-driven concept that Annie Withey originated 25 years ago. Annie’s is a pioneer of the new generation of company that does well by doing good, generating great value for all stakeholders. This is strategically the right time to pursue this combination because it brings operational, sourcing and distribution capabilities that enable Annie’s to build on its leadership position in the natural and organic market.”

The Annie’s Board of Directors has unanimously recommended that Annie’s stockholders accept the General Mills offer.  General Mills will launch a tender offer within ten business days to purchase all outstanding shares of Annie’s. General Mills’ offer will be subject to the tender of a majority of Annie’s shares and to certain other customary closing conditions including regulatory approval. The transaction is expected to close later in calendar 2014.

Annie’s financial advisor for the transaction is J.P. Morgan Securities LLC and its legal advisor is Proskauer Rose LLP.

About Annie’s

Annie’s, Inc. (NYSE: BNNY) is a natural and organic food company that offers great-tasting products in large packaged food categories. Annie’s products are made without artificial flavors, synthetic colors, and preservatives regularly used in many conventional packaged foods. Additionally, Annie’s sources ingredients so as to avoid synthetic growth hormones and genetically modified food ingredients. Today, Annie’s offers over 145 products and is present in over 35,000 retail locations in the United States and Canada. Founded in 1989, Annie’s is committed to operating in a socially responsible and environmentally sustainable manner. For more information, visit www.annies.com.

Forward-Looking Statements

Certain statements in this press release, including those relating to the future of our snacks business and achievement of our significant long-term growth potential, are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek” and similar terms or phrases.

The forward-looking statements contained in this press release are based on management’s current expectations, and are subject to uncertainty, changes in circumstances and significant risks. We cannot assure you that future developments affecting us will be those that we have anticipated.

Actual results may differ materially from the forward-looking statements contained in this press release due to changes in global, national, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include those disclosed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for fiscal 2014 filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 2, 2014 and our Form 10-Q for the quarter ended June 30, 2014 filed with the SEC on August 7, 2014, including risks relating to the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; the inability to complete the proposed tender offer or merger due to the failure to satisfy the conditions to completion of the tender offer and the merger; unexpected costs or unexpected liabilities that may arise from the transaction, whether or not consummated; continuation or deterioration of current market conditions; future regulatory or legislative actions that could adversely affect the companies; the outcome of any legal proceedings relating to the tender offer, the merger or the merger agreement; and risks to consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. Additional factors that may affect future results are contained in Annie’s filings with the SEC, which are available at the SEC’s website at www.sec.gov. Annie’s disclaims any obligation to update and revise statements contained in these materials based on new information or otherwise. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.

Notice to Investors

The tender offer described herein has not yet been commenced. The description contained herein is neither an offer to purchase nor a solicitation of an offer to sell securities of Annie’s. At the time the tender offer is commenced, General Mills and its wholly owned subsidiary intend to file a Tender Offer Statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer, and Annie’s intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. General Mills, its wholly owned subsidiary and Annie’s intend to mail these documents to the stockholders of Annie’s. These documents will contain important information about the tender offer and stockholders of Annie’s are urged to read them carefully when they become available. Stockholders of Annie’s will be able to obtain a free copy of these documents (when they become available) and other documents filed by Annie’s or General Mills with the SEC at the website maintained by the SEC at www.sec.gov. In addition, the Schedule TO and related exhibits, including the offer to purchase, forms of letters of transmittal, and other related tender offer documents may be obtained (when available) for free by contacting General Mills at Number One General Mills Boulevard, Minneapolis, Minnesota 55426 and the Schedule 14D-9 may be obtained (when available) for free by contacting Annie’s at 1610 Fifth Street, Berkeley, California 94710.

CONTACT:  

Ed Aaron
510-558-7574
303-868-5551
ir@annies.com

(IPAS) to Explore Strategic Alternatives

(DGTW) to Open up Its Vast Domain Portfolio for the First Time for Leases

Moving the Portfolio From a Holding Position to a Leasing Position Creates a Recurring $4 Million Revenue Model for Growth at Maturity

(RADA) Announces Second Quarter and First Half 2014 Results

NETANYA, Israel, Sept. 8, 2014  — RADA Electronic Industries Ltd. (Nasdaq:RADA) today announced its financial results for the second quarter and the six months ended June 30, 2014.

2014 Second quarter Results

Revenues totaled $6.4 million, 23% increase compared to $5.2 million in the second quarter of 2013.

Gross Profit totaled $2.04 million, 164% increase compared to $0.8 million in the second quarter of 2013.

Operating expenses totaled $1.4 million, 11% increase compared to $1.3 million in the second quarter of 2013.

Financial Expenses totaled $262,000, 43% decrease compared to financial expenses of $459,000 in the second quarter of 2013.

As a result, the Company reported Net Income of $385,000, or $0.04 per share, for the second quarter of 2014 compared to a net loss of $935,000 or $0.10 per share, for the second quarter of 2013.

First Half 2014 Results

Revenues totaled $11.8 million, 11% increase compared to $10.6 million for the same period in 2013.

Gross profit totaled $3.7 million, 124% increase compared to $1.6 million for the same period in 2013.

Operating expenses totaled $2.6 million, 9% decrease compared to $2.8 million for the same period in 2013. 

Financial expenses totaled $555,000, 41% decrease compared to financial expenses of $934,000 for the same period in 2013.  

As a result, the Company reported Net Income of $542,000 or $0.06 per share for the six months ended June 30, 2014, compared with a net loss of $2,100,000 or $0.23 per share, for the comparable period in 2013.

Management Comment

Commenting on the results, Zvika Alon, RADA’s Chief Executive Officer said, “The increase in gross margin to approximately 32% of our total revenues, is attributable in large measure to the high margin programs that accounted for a significant portion of our revenues during this quarter. As well as the reduction in financial expenses, these two major factors generated the growth in our net profit. We have increased our marketing expenses to pursue new business, in particular in our Radars product line, which has gained operational experience in various applications during the recent Operation Protective Edge and is expected to account for a growing part of our future revenues. We expect to continue the year with similar gross margins and therefore maintain our expectation for favorable 2014 results.”

About RADA

RADA Electronic Industries Ltd. is an Israel-based defense electronics contractor. The Company specializes in the development, production, and sales of Tactical Land Radar for Force and Border Protection, Inertial Navigation Systems for air and land applications and Avionics Systems and Upgrades.

Note: Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such risk uncertainties and other factors include, but are not limited to, changes in general economic conditions, risks in product and technology developments, market acceptance of new products and continuing product demand, level of competition and other factors described in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.

CONTACT: Shiri Lazarovich- C.F.O
         RADA Electronic Industries Ltd.
         Tel: +972-9-8921111
         Shiri.Lazarovich@rada.com